JP7224303B2 - 薬剤、組成物、及びそれに関連する方法 - Google Patents

薬剤、組成物、及びそれに関連する方法 Download PDF

Info

Publication number
JP7224303B2
JP7224303B2 JP2019563067A JP2019563067A JP7224303B2 JP 7224303 B2 JP7224303 B2 JP 7224303B2 JP 2019563067 A JP2019563067 A JP 2019563067A JP 2019563067 A JP2019563067 A JP 2019563067A JP 7224303 B2 JP7224303 B2 JP 7224303B2
Authority
JP
Japan
Prior art keywords
compound
insulin
glucose
cells
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520904A5 (enExample
JP2020520904A (ja
Inventor
ラン，ジージェン
パワー，ローナン
イアニクーリス，アレキサンドロス
ヤーラムレディ，ティルパティ，レディ
Original Assignee
オールテック，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オールテック，インク． filed Critical オールテック，インク．
Publication of JP2020520904A publication Critical patent/JP2020520904A/ja
Publication of JP2020520904A5 publication Critical patent/JP2020520904A5/ja
Application granted granted Critical
Publication of JP7224303B2 publication Critical patent/JP7224303B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2019563067A 2017-05-19 2018-05-01 薬剤、組成物、及びそれに関連する方法 Active JP7224303B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508730P 2017-05-19 2017-05-19
US62/508,730 2017-05-19
PCT/US2018/030371 WO2018212980A1 (en) 2017-05-19 2018-05-01 Pharmaceutical agents, compositions, and methods relating thereto

Publications (3)

Publication Number Publication Date
JP2020520904A JP2020520904A (ja) 2020-07-16
JP2020520904A5 JP2020520904A5 (enExample) 2021-06-17
JP7224303B2 true JP7224303B2 (ja) 2023-02-17

Family

ID=64274560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563067A Active JP7224303B2 (ja) 2017-05-19 2018-05-01 薬剤、組成物、及びそれに関連する方法

Country Status (11)

Country Link
US (2) US11014954B2 (enExample)
EP (1) EP3624809A4 (enExample)
JP (1) JP7224303B2 (enExample)
CN (2) CN110545822A (enExample)
AU (1) AU2018269403B2 (enExample)
CA (1) CA3061893A1 (enExample)
NZ (1) NZ758538A (enExample)
RU (1) RU2765286C2 (enExample)
SA (1) SA519410561B1 (enExample)
SG (1) SG11201909932YA (enExample)
WO (1) WO2018212980A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545822A (zh) * 2017-05-19 2019-12-06 全技术公司 药剂、组合物及其相关方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055016A1 (en) 2001-03-22 2003-03-20 Zhen Huang Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
JP2009511593A (ja) 2005-10-13 2009-03-19 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシンレセプターアゴニスト
WO2015137983A1 (en) 2014-03-14 2015-09-17 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
US8796241B2 (en) 2007-08-29 2014-08-05 Adam Lubin Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
HK1216506A1 (zh) 2013-03-15 2016-11-18 Alltech, Inc. 含硒組合物及其治療和預防與線粒體功能障礙有關的疾病或病症的應用
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
CN110545822A (zh) 2017-05-19 2019-12-06 全技术公司 药剂、组合物及其相关方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055016A1 (en) 2001-03-22 2003-03-20 Zhen Huang Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
JP2009511593A (ja) 2005-10-13 2009-03-19 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシンレセプターアゴニスト
WO2015137983A1 (en) 2014-03-14 2015-09-17 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof

Also Published As

Publication number Publication date
CN120647702A (zh) 2025-09-16
US20210238216A1 (en) 2021-08-05
BR112019022918A2 (pt) 2020-05-26
AU2018269403A1 (en) 2019-11-14
CA3061893A1 (en) 2018-11-22
US20200123191A1 (en) 2020-04-23
NZ758538A (en) 2025-08-29
EP3624809A4 (en) 2021-03-03
SA519410561B1 (ar) 2024-03-06
US11014954B2 (en) 2021-05-25
AU2018269403B2 (en) 2025-03-27
JP2020520904A (ja) 2020-07-16
SG11201909932YA (en) 2019-11-28
CN110545822A (zh) 2019-12-06
RU2019134865A3 (enExample) 2021-06-30
WO2018212980A1 (en) 2018-11-22
RU2765286C2 (ru) 2022-01-28
EP3624809A1 (en) 2020-03-25
US11613552B2 (en) 2023-03-28
RU2019134865A (ru) 2021-06-21

Similar Documents

Publication Publication Date Title
AU2016222315B2 (en) Compositions of selenoorganic compounds and methods of use thereof
WO2020244454A1 (zh) 五环三萜皂苷化合物的医药用途及其药物组合物
JP2022501331A (ja) 少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ−アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法
JP2019531320A (ja) Ｓｓａｏ／ｖａｐ−１阻害剤とｓｇｌｔ２阻害剤とを含む組合せ、その使用
JP7224303B2 (ja) 薬剤、組成物、及びそれに関連する方法
JP2003519660A (ja) 耐糖能に影響を与える薬剤を調製するための、環状エーテルの使用
JP2012072136A (ja) 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品
WO2020067832A1 (ko) 티아민 유도체를 포함하는 고코르티솔증 예방 또는 치료용 조성물
JP2024512744A (ja) ３－（４－（ベンジルオキシ）フェニル）ヘキサ－４－イン酸誘導体の新規用途
US20250009692A1 (en) Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
CN107427480A (zh) 用于预防和/或治疗脂肪性肝炎的脂肪酸酰胺
EP3144001B1 (en) Compositions of selenoorganic compounds and methods of use thereof
BR112019022918B1 (pt) Compostos farmacêuticos contendo selênio para modulação do metabolismo da glicose, composições farmacêuticas e seus usos
HK40017181A (en) Pharmaceutical agents, compositions, and methods relating thereto
US12138272B2 (en) Methods and compositions for treating amyotrophic lateral sclerosis
WO2024102114A1 (en) Methods and compositions for treating wolfram syndrome
HK1235284B (en) Compositions of selenoorganic compounds and methods of use thereof
HK1235284A1 (en) Compositions of selenoorganic compounds and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230207

R150 Certificate of patent or registration of utility model

Ref document number: 7224303

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150